The conventional approach to qualitative and quantitative analyses of hemoglobin (Hb) molecules for the diagnoses of hemoglobinopathies requires a combination of tests. We used an automated HPLC (VARIANT ) system to study ␣-thalassemia and ␤-thalassemia syndromes in Thailand. The beta-thalassemia short program is applicable to the diagnosis of ␣-thalassemia and ␤-thalassemia disorders, including Hb H, EA Bart's disease, and EF Bart's disease, in adults, newborns, and fetuses. The system cannot quantify accurately certain Hb molecules, such as Hb H and Hb Bart's. The alphathalassemia short program was therefore developed and used to quantify Hb Bart's to detect ␣-thalassemia genotypes in cord blood. This automated HPLC system is an alternative approach to the diagnosis of complicated thalassemia syndromes in Thailand and Southeast Asia.
The conventional approach to qualitative and quantitative analyses of hemoglobin (Hb) molecules for the diagnoses of hemoglobinopathies requires a combination of tests. We used an automated HPLC (VARIANT ) system to study ␣-thalassemia and ␤-thalassemia syndromes in Thailand. The beta-thalassemia short program is applicable to the diagnosis of ␣-thalassemia and ␤-thalassemia disorders, including Hb H, EA Bart's disease, and EF Bart's disease, in adults, newborns, and fetuses. The system cannot quantify accurately certain Hb molecules, such as Hb H and Hb Bart's. The alphathalassemia short program was therefore developed and used to quantify Hb Bart's to detect ␣-thalassemia genotypes in cord blood. This automated HPLC system is an alternative approach to the diagnosis of complicated thalassemia syndromes in Thailand and Southeast Asia.
Thalassemia and hemoglobinopathies, a group of autosomal-recessive inherited human disorders, are prevalent in many parts of the world. Heterozygote screening and genetic counseling are essential for the prevention and control of severe thalassemia diseases, i.e., hemoglobin (Hb) 5 Bart's hydrops fetalis (␣-thalassemia 1/␣-thalassemia 1), homozygous ␤-thalassemia, and ␤-thalassemia/Hb E. Diagnoses of thalassemia and abnormal Hbs can be performed at three different stages of development: the prenatal, neonatal, and adult stages. Conventional methods, including erythrocyte indices and morphology, Hb electrophoresis, quantitation of Hb A 2 , Hb E, and Hb F, and detection of erythrocytes containing Hb H inclusion bodies, provide an accurate diagnosis (1) (2) (3) (4) . Although measurement of Hb A 2 and Hb E by cellulose acetate electrophoresis and elution (5) and microcolumn chromatographic (6) techniques are reproducible and accurate, they are labor-intensive and time-consuming.
HPLC is a sensitive and precise method for detecting thalassemia and abnormal Hbs (7) (8) (9) (10) . It has become the preferred method for thalassemia screening because of its speed and reliability. An automatic HPLC system (VARIANT , Bio-Rad) has been developed primarily for the detection of ␤-thalassemia disorders such as ␤-thalassemia carriers, Hb S and Hb C. But information is quite limited about using such a system to study the complicated ␣-thalassemia and ␤-thalassemia syndromes in Southeast Asia (11) . In this study, we used the automatic HPLC system set up with the alpha-thalassemia short (ATS) program that we developed and with the betathalassemia short (BTS) program to detect various types of thalassemias in both prenatal and postnatal specimens.
Materials and Methods subjects
Department of Obstetrics and Gynecology, Siriraj Hospital. Thirty blood samples obtained at 16 -24 weeks of gestation from fetuses whose parents were at risk of having severe thalassemia diseases were also studied. The project was approved by the Human Experimental Committee of Mahidol University, Thailand.
procedures
Erythrocyte indices and Hb concentrations were determined using an automatic cell counter, the Sysmex NE 1500 (TOA). Quantitation of Hb A 2 , Hb E, Hb A, and Hb F was performed by the BTS program; quantitation of Hb Bart's was performed by the ATS program on the Bio-Rad VARIANT, a fully automated HPLC system that uses double wavelength detection (415 and 690 nm). The ATS program, developed by the manufacturer, has been designed to separate and quantitate Hb Bart's from all other Hbs in a 6 min run. Hb Bart's and total Hbs elute at 1.70 and 3.15 min. This program uses a 3 cm ϫ 0.46 cm cartridge packed with a 5-m porous silica-based weak cation exchange material. The analytes are eluted at a flow rate of 2 mL/min, using a step gradient of two phosphate buffers that differ in pH and ionic strength. An in-line prefilter is installed between the injector and the column. Quantitation is based on a specific Hb Bart's calibrator. Samples of whole blood (5 l in 2 mL of buffer) are hemolyzed before injection. The hemolysate (20 L) is injected onto the cartridge for analysis. All reagents were provided by the manufacturer and used according to the manufacturer's instructions.
The VARIANT system was compared with an electrophoresis/elution method (5) for Hb A 2 (E) measurement and against the alkali denaturation method of Betke et al. (12) for Hb F measurement in a total of 245 healthy, ␤-thalassemia trait, Hb E trait, or ␤-thalassemia/Hb E disease samples.
In the cord-blood study Hb types, including Hb Bart's and Hb Constant Spring (Hb CS), were also confirmed by isoelectric focusing (Isolab). The quantitation of Hb Bart's by HPLC was also compared with microcolumn chromatography by analyzing 50 cord-blood samples with a commercial kit, Quik-Sep (Isolab). The presence of ␤-thalassemia and Hb E in cord-blood samples was confirmed by dot blot hybridization between the amplified DNA and the allele-specific oligonucleotide probes (13, 14) ; in fetal blood samples, ␤-thalassemia and Hb E were confirmed by reverse dot blot hybridization (15) . Detection of ␣-thalassemia 1, ␣-thalassemia 2 (both the rightward, -␣ 3.7 , and the leftward, -␣ 4.2 , deletion types), and Hb CS was by PCR, as described previously (16 -18) .
Results

evaluation of the performance of the hplc system
Chromatograms of Hbs from various phenotypes of thalassemia syndromes. The VARIANT BTS program can differentiate several Hbs during a screening study. The chromatogram of a healthy subject with Hb A 2 and Hb A is shown in Fig.  1A . Hb F was eluted at 1.38 min, Hb A at 2.64 min, and Hb A 2 at 3.84 min; the total analysis time was 6.5 min. Fig. 1B illustrates the ability of BTS program to distinguish various Hbs in the Lyphochek Hemoglobin A2/F control (Bio-Rad Laboratories). In samples with the ␤-thalassemia trait, the chromatogram is similar to that of the nondiseased sample, but the concentration of Hb A 2 was increased. Mutations causing ␤-thalassemia produce a deficit of ␤-globin production that ranges from minimal (␤ ϩ -thalassemia) to a complete absence of ␤-globin (␤ 0 -thalassemia). In homozygous ␤-thalassemia, the chromatogram shows the prominence of Hb F; the absence of or minor amounts of Hb A, depending on the genotype of ␤-thalassemia (␤ 0 -thalassemia or ␤ ϩ -thalassemia, respectively); and an unaffected or increased Hb A 2 concentration (Fig. 1C) . Hb E was eluted at the same retention time as the Hb A 2 found in healthy samples or samples with the ␤-thalassemia trait. Usually 25-30% was detected in Hb E heterozygotes, and almost 100% was detected in Hb E homozygotes ( Fig. 1, D and E). The chromatogram also shows the presence of a Hb A peak in ␤ ϩ -thalassemia/Hb E disease, whereas there was no Hb A in ␤ 0 -thalassemia/Hb E disease (Fig. 1F) .
In Hb H disease, there were one or two abnormal peaks present at the retention time of 1 min, before the Hb F peak. The two peaks represent Hb Bart's and Hb H, respectively (Fig. 1G ). For EA Bart's disease (␣-thalassemia 1/␣-thalassemia 2-EA), the chromatogram showed increased concentrations of Hb E (ϳ15%) and Hb F (ϳ2-3%; Fig. 1H ). For EF Bart's disease (␣-thalassemia 1/␣-thalassemia 2-EE or ␣-thalassemia 1/␣-thalassemia 2-EF), the chromatogram illustrates the predominance of Hb F and Hb E, with minor amounts of Hb Bart's ( Fig. 1I )
In healthy newborns, the major Hb was Hb F (Ͼ80%), and Hb A was found in small amounts ( Fig. 2A) . The Hb E peak was also detected in newborns with Hb E syndromes (Fig. 2B ). In newborns with ␣-thalassemia diseases, the Hb Bart's peak was also detected (Fig. 2, C and E). The pattern of the chromatogram of Hb Bart's hydrops fetalis was very specific, and the major Hb eluted at almost 0 retention time (Fig. 2C) . Because the BTS program cannot quantitate Hb Bart's, the ATS program was developed to identify and quantitate Hb Bart's in ␣-thalassemia (Fig. 2, D and F) . The presence of Hb Bart's (first peak) was confirmed by an isoelectric focusing method. The second peak in the chromatogram represents other Hb derivatives.
Comparison of concentrations of Hb A 2 , Hb E, HB F, and Hb
Bart's measured by HPLC and conventional methods. Precision studies were performed using blood samples with different concentrations of Hb A 2 and Hb F. Each sample was analyzed in 20 replicates for each HPLC assay for the within-run precision study and analyzed once a day for 10 consecutive days for the between-days precision study. 
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thalassemia screening by hplc
Postnatal screening with adult blood. A total of 4147 adult blood specimens were screened for thalassemias and hemoglobinopathies. Subjects were from the routine hematology clinic. Apparently healthy individuals with Hb concentrations Ͻ120 g/L were excluded to avoid the effect of iron deficiency anemia. Table 2 shows that the concentration of Hb A 2 increased with the ␤-thalassemia trait, and the Hb F concentration increased (Ն1%) in 40% of those cases. Hb concentrations Ͼ10% at the position of Hb A 2 were assumed to be Hb E. The concentration of Hb E was 27.8 Ϯ 7.5% in the heterozygous state and 90.2 Ϯ 4.9% in the homozygous state. In EA Bart's disease, the Hb E concentration was 14.9 Ϯ 1.6%, with the appearance of an abnormal peak at the Bart's position. A presumptive diagnosis was made for the ␣-thalassemia 1 trait when patients had a low mean corpuscular volume (MCV, 70 Ϯ 6.9 ϫ 10 Ϫ15 L) and concentrations of Hb A 2 within the reference range without anemia. Although the VARIANT BTS program cannot measure the concentration of Hb Bart's and Hb H in Hb H disease, the abnormal peaks representing these Hbs were shown (Fig. 1G) . Diagnosis of Hb H disease was also confirmed by the finding of erythrocytes containing inclusion bodies.
Neonatal screening with cord blood. A total of 521 cord-blood samples were screened with the two VARIANT programs. Of these, 195 cases (37.4%) were found to have thalassemias and hemoglobinopathies. The presence of Hb E, Hb Bart's, Hb H, and an abnormal Hb was confirmed by isoelectric focusing. Dot blot hybridization with the allele-specific oligonucleotide probes detected the ␤ E -globin gene in 141 cord blood samples in which the Hb concentration at the Hb A 2 position was Ͼ2% (Table  3) . Of these, 12 cases were found to be homozygous for Hb E; one case was later found to be EF Bart's disease (␣-thalassemia 1/␣-thalassemia 2-EE), with a Hb E concentration of 30.1% and a Hb Bart's concentration of 17.55%. The Hb E concentration in the remaining cases of homozygous Hb E ranged between 3.9% and 14.9% with a mean Ϯ SD ϭ 8.0 Ϯ 3.55%. Two newborns carrying one allele of ␤ E were also found to have EA Bart's disease (␣-thalassemia 1/␣-thalassemia 2-EA) and homozygous Hbcs (CS/CS-EA), respectively. A newborn with Hb A 2 (E) (2% of total Hb) was also found to have ␤ 0 -thalassemia/Hb E disease by dot blot hybridization, which dem- Clinical Chemistry 44, No. 4, 1998 onstrated the presence of a mutation in the IVS II nucleotide 654, a mutation of C3 T in one allele and of the ␤ E -globin gene in the other. PCR detected ␣-thalassemia determinants, including ␣-thalassemia 1, ␣-thalassemia 2, and Hb CS in 70 cordblood specimens, of which 15 cases also had Hb E. Of these, two were found to have Hb H disease, one had EA Bart's disease, one had EF Bart's disease, and two were homozygous for Hb CS (Hb CS/Hb CS). The concentrations of Hb Bart's determined by the ATS program of VARIANT were all Ͼ15% except for a case of homozygous Hb CS coinherited with Hb E, in which the Hb Bart's was 8.3% (Table 3 ). Because the Hb Bart's concentrations were similar, DNA analysis was necessary to distinguish ␣-thalassemia syndromes among the ␣-thalassemia 1 heterozygotes, the ␣-thalassemia 2 homozygotes, and compound heterozygotes for ␣-thalassemia 2/Hb CS and among Hb CS heterozygotes, ␣-thalassemia 2 heterozygotes, and healthy individuals. Although Hb Bart's in ␣-thalassemia 2 heterozygotes ranged between 1.2% and 2.6%, 40 cases (7.6%) of newborns with the nondiseased ␣-globin genotype also had Hb Bart's (1.2-2.6%).
Prenatal diagnosis with fetal blood. Cordocentesis was performed in the pregnancies at risk of having thalassemic fetuses at the gestational ages of 16 -24 weeks. Chromatograms of thalassemia syndromes prenatally diagnosed by the VARIANT BTS program were similar to those of the cord blood specimens. The fetuses with ␤-thalassemia traits had similar concentrations of Hb F and Hb A to the healthy fetus (Table 4 ). In the Hb E heterozygote, 0.8 -1.4% of the Hb E was Hb E at the Hb A 2 position, which was detected in addition to Hb A, whereas there was no Hb A in fetuses with homozygous Hb E and ␤ 0 -thalassemia/HbE disease. The latter two conditions were distinguished by DNA analysis. Hb Bart's hydrops fetalis also produced no Hb A, and only Hb Bart's was demonstrated by HPLC.
Discussion
The BTS program was designed to detect Hb A 2 , Hb F, and abnormal Hbs such as Hb S and Hb C; these were clearly separated from the normal Hb. Hb C usually migrates to the same position as Hb A 2 on electrophoresis at alkali pH and is misdiagnosed as Hb E, with a concentration of 30% for the heterozygous state (19) . However, some abnormal Hbs, such as Hb E, Hb Tak, Hb D, and Hb Lepore, will also coelute with Hb A 2 . Therefore, samples that have Ͼ10% Hb A 2 should be tested for the possible presence of other Hb variants. Different concentrations of Hbs may distinguish each abnormal Hb. For example, the percentage of Hb D eluted at the Hb A 2 peak in the Hb D heterozygote was 38.9%, which was higher than Hb E or Hb A 2 in the usual cases for the Hb E heterozygote (25-30%) or for the ␤-thalassemia heterozygote (4 -7%). Although the BTS program could not quantitate Hbs Bart's and Hbs that were eluted at a retention time between 0 and 1 min, BTS can qualitatively diagnose common ␣-thalassemia diseases, including Hb H and EA Bart's or EF Bart's diseases (Fig. 1) .
The low variability for the measurement of Hb A 2 and Hb E was comparable with the other methods for Hb A 2 quantitation; the CV of Hb A 2 by microcolumn chromatography was 2.5%, and that by elution from cellulose acetate electrophoresis was Ͼ3.6% (5) . The other automated HPLC, the DIAMAT Analyzer System, gave a CV ranging from 1.8% to 4.1% (20) . The within-run precision for Hb F in this study was also appreciably better than that of other means. CVs for Hb F by radial immunodiffusion and alkali denaturation range from 3.95% to 5.74% and from 1.4% to 9.1%, respectively, whereas the CV of the HPLC method was 4.5% (21) .
In adults, an increased Hb A 2 in the range of 4 -7% is specific for the ␤-thalassemia trait in almost all cases (22, 23) . Our study confirmed the identification of the ␤-thalassemia trait and the Hb E trait, using the Hb A 2 (E) concentration determined by HPLC (Table 2) . However, iron deficiency anemia remains a problem in differential diagnosis of ␣-thalassemias, ␤-thalassemias, and Hb E carriers. Iron deficiency anemia has been shown to decrease Hb A 2 and E concentrations and must be ruled out before a diagnosis is made (24) . In addition, coinheritance of the ␣-thalassemia gene in ␤-thalassemia or Hb E also affects their phenotypic expression. The concentration of Hb E decreased proportionally with the number of ␣-globin gene deletions, from 25-30% in the heterozygote with a nondiseased ␣-globin genotype to 19 -21% in Hb E with ␣-thalassemia 1 or to 11-15% in EA Bart's disease (25) (26) (27) (28) . Coinheritance of ␣-thalassemia 1 also affects MCV in the ␤-thalassemia trait. The MCV was found to be increased HPLC is also useful for large-scale screening of thalassemias and hemoglobinopathies in the neonatal period. Although newborns with ␤-thalassemia cannot be distinguished from healthy newborns because ␤-globin gene expression is not fully functional at this stage of development, the ability of the VARIANT BTS program to detect all cases of Hb E syndromes and demonstrate the absence of Hb A is a great advantage for the diagnosis of ␤ 0 -thalassemia diseases (Table 3 ). However, both homozygous Hb E (asymptomatic) and ␤ 0 -thalassemia/Hb E diseases had similar chromatograms composed of Hb E and Hb F. Although newborns with homozygous Hb E have a tendency to have higher concentrations of Hb E (3.9 -15%) than those with ␤ 0 -thalassemia/Hb E disease (2%), DNA analysis is necessary to differentiate the two syndromes .
Our study also showed that the qualitative demonstration of Hb Bart's and Hb H using the VARIANT BTS program aids in the diagnosis of ␣-thalassemia syndromes during the neonatal period. All cases of Hb Bart's hydrops fetalis are detected, and all cases of Hb H disease and most cases of ␣-thalassemia trait were also detected. The ATS program helps to quantitate the amount of Hb Bart's and provides a diagnosis for newborns with Hb H disease whose Hb Bart's was increased to 20 -25% (Table  3) . However, as mentioned in previous studies, diagnosis of ␣-thalassemia cannot rely solely on the amount of Hb Bart's because the concentration of Hb Bart's in each phenotype may be similar (29, 30) . It should also be noted that in the neonatal period, newborns with ␣-thalassemia syndromes, including Hb H, EA Bart's disease, EF Bart's diseases, the ␣-thalassemia 1 trait, and homozygous ␣-thalassemia 2, have low MCV values, whereas those with ␤-thalassemia syndromes still have MCV values within the reference range. This is because full synthesis of the ␣-globin chain can be attained in the fetal stage, and the abnormalities would interfere with Hb molecules produced thereafter, resulting in abnormal erythrocyte production.
In the fetal stage, the patterns of chromatograms with various genotypes of thalassemia were similar to those obtained from cord blood. Although the concentration of Hb A and Hb E were lower than those measured during the neonatal period, the disappearance of Hb A and the specific feature of chromatograms can help in prenatal diagnosis of severe thalassemia diseases.
